SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented silver dihydrogen citrate (SDC)
antimicrobial, announced today the Company will present at Rodman &
Renshaw's 2016 Annual Global Investment Conference on Tuesday, September
13, 2016 at the Lotte New York Palace Hotel in New York City.
Hank
R. Lambert, CEO, will present at 3:25pm EDT on Tuesday, September 13th
and discuss:
Progress of the commercialization of SDC as a highly effective food
safety solution, and
The status of its FDA approved PURE Control® antimicrobial
Now being commercialized as a fresh produce processing aid, and
Status of ongoing USDA in-plant testing as a raw poultry
processing aid in Online Reprocessing (OLR)
In July PURE received a USDA
No Objection Letter for use in Poultry Processing for
Pre-OLR and Post Chill Applications
SDC test results demonstrate materially significant reduction in Salmonella
contamination in poultry – and materially significant reduction in Salmonella,
Listeria and E. coli contamination in produce.
If you are an institutional investor, and would like to attend the
Company’s presentation, please click on the following link ( )
to register for the conference. Once your registration is confirmed, you
will be prompted to log into the conference website to request a
one-on-one meeting with the Company.
The presentation will be webcast live with slides (and available for
replay) and can be accessed on the Company's website, .
About Rodman & Renshaw
Rodman & Renshaw, a unit of H. C. Wainwright & Co., LLC, is dedicated to
providing corporate finance, strategic advisory and related services to
public and private growth companies across multiple sectors and regions.
The Rodman team has been the leader in the PIPE (private investment in
public equity) and RD (registered direct offering) transaction markets.
According to Sagient Research Systems, the team has been ranked the #1
Placement Agent in terms of the aggregate number of PIPE and RD
transactions cumulatively since 1998.
About PURE Bioscience, Inc.PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety arena --
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and it mitigates bacterial
resistance. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at .
Forward-looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from the
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s failure
to implement or otherwise achieve the benefits of its proposed business
initiatives and plans; acceptance of the Company's current and future
products and services in the marketplace, including the Company’s
ability to convert successful evaluations into customer orders; the
ability of the Company to develop effective new products and receive
required regulatory approvals for such products, including the required
data and regulatory approvals required to use its SDC-based technology
as a direct food contact processing aid in raw meat processing;
competitive factors; dependence upon third-party vendors, including to
manufacture its products; and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission (the
SEC), including its Form 10-K for the fiscal year ended July 31, 2015,
its Form 10-Q for the first quarter ended October 31, 2015 and its Form
10-Q for the second quarter ended January 31, 2016, and its Form 10-Q
for the third quarter ended April 30, 2016. You should not place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Contacts
PURE Bioscience, Inc.Hank Lambert, CEO619-596-8600 ext.103hlambert@purebio.comorBibicoff
+ MacInnis, Inc.Terri MacInnis, VP of IR818-379-8500terri@bibimac.comorRedwood
Investment GroupTom Hemingway, 714-978-4425tomh@redwoodfin.com
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.